MagSense Utility as a Potential MRI Contrast Agent
Released
Released
Announcement PDF
®
IMAGION BIOSYSTEMS LIMITED
(ASX: IBX)
9 September 2019
Imagion presents positive new data at World Molecular Imaging Congress
Study reports MagSense™ utility as a potential MRI contrast agent
MELBOURNE — Imagion Biosystems Limited (ASX: IBX) (the Company), a company dedicated to
improving healthcare through the earlier detection of cancer is presenting new data which further
demonstrates the potential imaging utility of its nanoparticles for detecting HER2 breast cancer cells. The
data was presented as a scientific poster at the 2019 World Molecular Imaging Congress being held in
Montreal, Canada, September 4 -7.
This study is the Company’s first reported results demonstrating that the anti-HER2 nanoparticles used in
Imagion’s MagSense™ technology, which provide specific targeting of cancerous cells, may also have
potential as an MR imaging contrast agent. Thus, importantly, the study shows the MagSense™
nanoparticles may be equally effective as a multi-modal molecular imaging agent, generating detectable
signals in two different imaging methods - super magnetic relaxometry (SPMR) and magnetic resonance
imaging (MRI).
“This study provides further evidence and insight into the effectiveness of our nanoparticles and their ability
to specifically bind to targeted tissue, where they then act as a magnetic tag or beacon and a non-invasive
imaging tool” said Bob Proulx, CEO of Imagion Biosystems.
“While development of our proprietary magnetic relaxometry technology has been our focus to date, this
new preliminary work shows the potential for our MagSense™ nanoparticles to work with MRI and could
open up a new commercial pathway as an contrast agent that can be used to improve the effectiveness of
MRI in the detection and monitoring of HER2 breast cancer.”
Imagion’s proprietary MagSense™ technology works by using the tiny bio-safe nanoparticles coated with
tumour targeting antibodies to tag the cancer. MagSense™ sensors are able to detect the particles which
have become attached to cancer cells which act like a magnetic beacon because bone and normal tissue
are transparent to the detection platform. SMPR uses very low magnetic fields, making it safer for patients
and less expensive to manufacture and install.
In the MRI setting, contrast agents are used to enhance the image and improve resolution. However, todate, imaging agents have been general purpose, creating contrast at tissue boundaries but not providing
functional imaging utility. A targeted MagSense™ nanoparticle detectable by SPMR, that also could be used
as a contrast agent to enhance an MR image of specific tissue would create an opportunity for Imagion to
work with the large installed base of existing MRI machines.
“Our toxicology studies have already demonstrated that our nanoparticles should be safe for use in humans
and we remain focused on the completion of our first-in-human studies and the well-defined shortest path to
commercialization. However, we are encouraged by these early results and plan to embark on further
studies, to explore how our technology could be optimally positioned alongside existing clinical practices to
enhance its commercial potential,” said Mr Proulx.
A link to the poster, which was presented by Dr Marie Zhang, VP of Research and Pre-Clinical Development
at Imagion Biosystems, can be found here: https://imagionbiosystems.com/2019-world-molecular-imagingconference-poster/ The WMIC is the premier forum for scientists and clinicians focused on cutting-edge
advances in molecular imaging.
M:10790741_1 AYT
Imagion Biosystems Limited
ACN 616 305 027
Level 8, 555 Bourke Street, Melbourne VIC 3000
www.imagionbiosystem.com
®
-ENDS
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology.
Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases
earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian
Securities Exchange (ASX) in June 2017.
For further information please visit www.imagionbiosystems.com
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630
M:10790741_1 AYT
Australian Media & Investor Relations:
Kyahn Williamson, WE Buchan
ImagionBiosystems@we-buchan.com
+61-3-9866-4722
Imagion Biosystems Limited
ACN 616 305 027
Level 8, 555 Bourke Street, Melbourne VIC 3000
www.imagionbiosystem.com
Share your feedback
Discover